B7-H3(4Ig) [B7-H3b] (human) (rec.) (His)
390 CHF CHF 390.00
CHI-HF-201B7H3B-C05050 µgCHF 390.00
|Source/Host||HEK 293 cells|
|Sequence||Human B7-H3(4Ig) [B7-H3b] (aa 27-461) is fused at the C-terminus to a His-tag.|
|Biological Activity||Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells.|
|Endotoxin Content||<0.01EU/μg protein (LAL test; Lonza).|
Reconstitute 50µg vial with 100 µl sterile water to a concentration of 0.5mg/ml.
Add 1X PBS to the desired protein concentration.
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Other Product Data||NCBI reference NP_001019907.1: B7-H3b (human)|
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
PBS containing at least 0.1% BSA should be used for further dilutions.
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
B7-H3(4Ig) or B7-H3b has two additional Ig-like domains (one V- type and one C- type) and shows a ubiquituous expression pattern. B7-H3(4Ig) is expressed on dendritic cells as well as activated T, B and NK cells. Human (4Ig) binding to an undefined receptor has shown to be inhibitory to NK cell illing and cytokine release. It also seems to be required for late stage osteoblast differentiation.